Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6070489 | 0.81 | KMT2A (0.44) | KMT2AKDM4EMEN1POLBMAPT | |
| Cyclocreatine SCHEMBL7935371 | 0.81 | CYP2D6 (0.39) | KMT2AKDM4EPOLBTDP1TSHR | |
| Cyclocreatine SCHEMBL450343 | 0.81 | CYP2D6 (0.39) | KMT2AKDM4EPOLBTDP1TSHR | |
| Cyclocreatine SCHEMBL11796002 | 0.79 | CYP2D6 (0.38) | KMT2AKDM4EPOLBTDP1TSHR | |
| Cyclocreatine SCHEMBL1980714 | 0.78 | CYP2D6 (0.37) | KMT2AKDM4EPOLBTDP1TSHR | |
| Cyclocreatine SCHEMBL1981687 | 0.74 | INMT (0.40) | KMT2APOLBTSHR | |
| SCHEMBL12647102 | 0.72 | — | — | |
| SCHEMBL27454117 | 0.72 | ALDH1A1 (0.33) | POLBALDH1A1 | |
| SCHEMBL14537232 | 0.72 | BDKRB2 (0.33) | KMT2AMEN1TSHRSMN1; SMN2RAB9A | |
| SCHEMBL19719147 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014152042-A2 | IMPROVED TECHNIQUES, SYSTEMS AND MACHINE READABLE PROGRAMS FOR MAGNETIC RESONANCE | MILLIKELVIN TECHNOLOGIES LLC (US) | 2014-09-25 | — | — | WO | claimed |
| US-20140285192-A1 | TECHNIQUES, SYSTEMS AND MACHINE READABLE PROGRAMS FOR MAGNETIC RESONANCE | MILLIKELVIN TECHNOLOGIES LLC (US) | 2014-09-25 | — | — | US | claimed |
| EP-0426100-B1 | Stabilized enzyme compositions | ABBOTT LAB (US) | 1994-12-14 | — | — | EP | claimed |
| EP-0426100-A1 | Stabilized enzyme compositions | ABBOTT LABORATORIES (US) | 1991-05-08 | — | — | EP | claimed |
| US-20240180912-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | INSPIRNA, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-20230248751-A1 | NOVEL BIOENERGETIC/ANTI INFLAMMATORY THERAPY | NOUR HEART, INC. | 2023-08-10 | — | — | US | disclosed |
| WO-2023004308-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | INSPIRNA, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| EP-3950673-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | Inspirna, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3950673-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | Inspirna, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20210393563-A1 | METHODS FOR TREATING MICROGLIAL DYSFUNCTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-12-23 | — | — | US | disclosed |
| EP-3137447-B1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX INC (US) | 2021-06-30 | — | — | EP | disclosed |
| EP-3137447-B1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX INC (US) | 2021-06-30 | — | — | EP | disclosed |
| WO-1994016712-A9 | CREATINE PHOSPHATE, CREATINE PHOSPHATE ANALOGS, AND USES THEREFOR | — | 1994-09-15 | — | — | WO | disclosed |
| WO-1994016712-A1 | CREATINE PHOSPHATE, CREATINE PHOSPHATE ANALOGS, AND USES THEREFOR | AMIRA, INC. (US) | 1994-08-04 | — | — | WO | disclosed |
| US-5324731-A | Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated | AMIRA, INC. (US) | 1994-06-28 | — | — | US | disclosed |
| US-5321030-A | Administering for treatment or prevention | AMIRA, INC. (US) | 1994-06-14 | — | — | US | disclosed |
| EP-0557383-A1 | METHOD OF INHIBITING TRANSFORMATION, GROWTH AND METASTASIS OF CELLS IN WHICH PURINE METABOLIC ENZYME ACTIVITY IS ELEVATED | AMIRA, INC. (US) | 1993-09-01 | — | — | EP | disclosed |
| WO-1993012781-A2 | CREATINE ANALOGS HAVING ANTIVIRAL ACTIVITY | AMIRA, INC. (US) | 1993-07-08 | — | — | WO | disclosed |
| WO-1992008456-A2 | METHOD OF INHIBITING TRANSFORMATION, GROWTH AND METASTASIS OF CELLS IN WHICH PURINE METABOLIC ENZYME ACTIVITY IS ELEVATED | AMIRA, INC. (US) | 1992-05-29 | — | — | WO | disclosed |
| EP-0426100-A1 | Stabilized enzyme compositions | ABBOTT LABORATORIES (US) | 1991-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180912-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | KRAS, FOLR2, SLC19A1 | KMT2A 3661/4885KDM4E 3385/4885MEN1 3453/4885 |
| US-20210393563-A1 | METHODS FOR TREATING MICROGLIAL DYSFUNCTION | CHRNB2, PSEN2, CX3CR1 | KMT2A 2657/4885KDM4E 3658/4885MEN1 4782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.